Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the cheap side rather than as a fully valued turnaround story.
-
The share price has declined 29.6% over five years, which points to a company that has struggled to create positive long term returns for shareholders.
-
Recent progress in patient care technology and leadership changes can support sentiment on future profitability, but the global clinic footprint and execution on the FME Reignite plan still carry operational risks that matter for valuation.
-
On Simply Wall St’s broader checks, Fresenius Medical Care screens as undervalued in 5 of 6 areas, which leans toward the stock being priced below what its fundamentals suggest.
The stock’s next move may depend on whether the current share price already reflects these improvements in the business or still leaves a margin between market price and underlying fundamentals.
Find out why Fresenius Medical Care’s 1.3% return over the last year is lagging behind its peers.
Does Fresenius Medical Care Look Undervalued on Earnings?
The P/E multiple suits Fresenius Medical Care because earnings are a key focus for a mature, cash generative healthcare group. The stock currently trades at about 11.7x earnings, which is well below the broader Healthcare sector average of roughly 20.3x and a peer group average near 26.1x.
On Simply Wall St’s fair P/E estimate that blends the company’s growth profile, margins, size and risk, Fresenius Medical Care would trade closer to 24.4x. That is more than double the present 11.7x level, which indicates a sizeable gap between how the market prices the stock today and what that framework suggests might be reasonable. Despite the reported Q2 2026 operating income growth and the ongoing rollout of the 5008X CAREsystem, the current multiple still sits at a clear discount to those benchmarks.
Overall, Fresenius Medical Care stock appears undervalued on the current P/E multiple compared with both tailored and market reference points.
See what the numbers say about this price — find out in our valuation breakdown.
The Fresenius Medical Care Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for Fresenius Medical Care pick up where this valuation puzzle leaves off and explain the type of growth, margins, and earnings profile that would need to apply for the stock to be worth materially more or less than today’s price, based on the latest data. Each narrative presents Fresenius Medical Care’s implied fair value as a thesis about the business that you can track over time on the Community page, rather than as a single static snapshot.